Zacks Investment Research upgraded shares of Bayer (OTCMKTS:BAYRY) from a hold rating to a buy rating in a research report sent to investors on Wednesday. Zacks Investment Research currently has $36.00 price target on the stock.

According to Zacks, “As part of its strategy to complete the planned acquisition of Monsanto, Bayer inked an agreement to sell selected Crop Science businesses to BASF. With this agreement, the company will actively address the authorities’ possible concerns regarding the planned acquisition of Monsanto and facilitate a successful closing of the transaction by early 2018. The combined enterprise will be able to bring innovations to the market faster and provide its customers with better solutions. However, the company is facing generic competition for many of its products including the Yaz franchise (oral contraceptives). The generics of key drugs will negatively impact revenues. Yet, Bayer’s shares have outperformed the industry year to date. Estimates have increased ahead of the Q4 earnings results. The company has a positive record of earnings surprises in recent quarters.”

A number of other equities analysts have also recently issued reports on BAYRY. ValuEngine cut Bayer from a buy rating to a hold rating in a report on Friday, September 22nd. BNP Paribas upgraded Bayer from a neutral rating to an outperform rating in a report on Monday, September 25th. Three research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. The company has an average rating of Hold and a consensus price target of $36.00.

Shares of Bayer (OTCMKTS:BAYRY) traded up $0.02 on Wednesday, hitting $31.82. The company had a trading volume of 440,616 shares, compared to its average volume of 426,639. Bayer has a 12 month low of $26.98 and a 12 month high of $35.41. The company has a current ratio of 1.51, a quick ratio of 1.01 and a debt-to-equity ratio of 0.67. The company has a market cap of $105,070.00, a PE ratio of 27.91, a P/E/G ratio of 1.95 and a beta of 1.14.

Bayer (OTCMKTS:BAYRY) last issued its earnings results on Thursday, October 26th. The company reported $0.43 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.29 by $0.14. Bayer had a return on equity of 18.53% and a net margin of 10.88%. analysts anticipate that Bayer will post 2.27 earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This piece was first posted by Daily Political and is the sole property of of Daily Political. If you are reading this piece on another website, it was copied illegally and reposted in violation of United States & international trademark & copyright law. The original version of this piece can be accessed at https://www.dailypolitical.com/2018/01/18/bayer-bayry-upgraded-by-zacks-investment-research-to-buy.html.

About Bayer

Bayer AG is a life science company. The Company’s segments are Pharmaceuticals, Consumer Health, Animal Health and Covestro. The Pharmaceuticals segment focuses on prescription products, especially for cardiology and women’s healthcare, and on specialty therapeutics in the areas of oncology, hematology and ophthalmology.

Get a free copy of the Zacks research report on Bayer (BAYRY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Bayer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer and related companies with MarketBeat.com's FREE daily email newsletter.